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Abstract The single disulfide loop (Cys178-Cys213) of the prion
protein (PrP) may stabilize the conformation of this protein by
bridging the C-terminal K-helices. The substitution mutant
Cys178Ala fails to form the prion isoform PrPSc when expressed
in scrapie-infected neuroblastoma ScN2a cells (Muramoto et al.,
Proc. Natl. Acad. Sci. USA 93, 15457^15462). To investigate
the reasons for this failure, we introduced the C178A substitution
in the full length mouse PrP gene as well as in its N-terminally
truncated v23-88 version. The resulting mutants (C178A and
vC178A, respectively) were transiently expressed in N2a and
CHO cells. Wild-type PrP, wild-type v23-88 and the point
mutant E199K served as controls in these experiments.
Compared to the wild-type controls, the C178A mutants were
markedly resistant to proteolysis and they were also vastly
insoluble in sarcosyl. Studying the metabolic fate of the C178A
mutants, we found that in contrast to control PrP molecules,
these mutants (i) remained sensitive to the diagnostic endogly-
cosidase EndoH, (ii) failed to reach the cell surface and (iii)
congregated in large juxtanuclear spots. We surmise that these
severe trafficking abnormalities may contribute both to the
spontaneous aggregation of the C178A mutants and to their
reported inability to form PrPSc.
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1. Introduction
Prions [1] are proteinaceous agents that cause the transmis-
sible spongiform encephalopathies, which comprise infectious,
familial and sporadic diseases. Prions are thought to propa-
gate by refolding a normal glycoprotein of the host, the cel-
lular prion protein (PrP) PrPC, into an abnormal ‘prion’ con-
formation (reviewed in [2]). The resulting pathological
conformer, PrPSc, is in turn the only known component of
the infectious prion.
In addition to typical prion diseases in which infectious
prions propagate, PrP is also involved in metabolic disorders,
in which infectious prions have not been demonstrated. Bio-
chemical and cell biological attributes of PrP mutants crit-
ically determine their involvement in either type of disorders.
For instance, the correct subcellular targeting of PrPC precur-
sors is essential for their subsequent transformation into PrPSc
in prion-infected cells. Hence, preventing PrPC molecules from
exiting the ER-Golgi using brefeldin A (BFA) prevented the
formation of PrPSc in scrapie-infected cultured cells [3]. Stud-
ies have also shown that mishandling of several mutant PrPs
by the cell can lead to storage-like diseases as well as other
disorders [4,5]. In addition, several pathogenic mutants that
are linked to familial prion diseases in humans display slight
metabolic abnormalities when expressed in cultured cells [6].
Mutational analysis coupled with transgenetic experiments
have begun to uncover amino acid signals within PrP that are
essential for correct PrPC targetting as well as for prion for-
mation and propagation [5,7,8]. Using prion-infected mouse
neuroblastoma ScN2a cells, Prusiner and his colleagues [9]
recently showed that substituting an alanine for Cys178 (mouse
PrP numbering, see nomenclature in Section 2), thereby dis-
rupting the unique disul¢de loop, abolished the formation of
PrPSc. In mature wild-type (wt) PrP, the cysteines (at positions
178 and 213 of mouse PrP) are both oxidized [10] and the
resulting disul¢de loop is thought to stabilize the structure of
PrPC by linking the two carboxy-terminal helices [11,12].
Cys178 neighbors two other prominent residues. First, the im-
mediately adjacent D177 (homologous to codon 178 in hu-
mans) is substituted by an arginine in several European kin-
dreds su¡ering from familial CJD [13,14], as well as in
kindreds with fatal familial insomnia [15]. Also close to
Cys178 is the N-glycosylation site N180. While glycosylation
of PrP is not essential for the formation of protease-resistant
PrPSc [16], under-glycosylated PrP displays various metabolic
abnormalities [17,18] and unglycosylated PrPC displays weak
‘prion-like’ properties [19].
In this paper, we studied the cellular and biochemical prop-
erties of PrP with the C178A substitution. To this end, we
used the epitopically tagged chimeric PrP designated MHM2-
PrP [20]. We substituted an alanine for Cys178 in two di¡erent
PrP platforms: (i) full length MHM2-PrP and (ii) its trun-
cated version v23-88 (C178A and vC178A, respectively) and
transiently expressed these constructs in Chinese hamster ova-
ry (CHO) and N2a cells. We found that both C178A mutants
resisted higher levels of proteinase K than wt PrP and were
also largely insoluble in sarcosyl. Furthermore, both C178A
mutants su¡ered from profound subcellular tra⁄cking abnor-
malities, which probably result from their aggregation in the
early secretory pathway. We surmise that these abnormalities
may contribute to the inability of these mutants to produce
PrPSc in scrapie-infected cells [9].
2. Materials and methods
2.1. Materials
Cell culture reagents were purchased from Biological Industries (Bet
Haemek, Israel). Tissue culture plates were obtained from Miniplast
(Ein Shemer, Israel) or Nunc (Denmark). G418 and sulfo-NHS biotin
(cat #203189) were from Calbiochem (San Diego, CA, USA). Other
chemicals were from Sigma (St. Louis, MO, USA). Restriction en-
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zymes were from New England Biolabs (MA) and MBI-Fermentas
(Lithuania).
2.2. Nomenclature
The amino acid numbering of the mouse PrP is used throughout
this paper. Thus, Cys178 in MoPrP corresponds to Cys179 in human
PrP. MHM2-PrP [20] is a mouse-Syrian hamster chimeric PrP that
carries the epitope for the monoclonal antibody (mAb) 3F4 [21]. Here,
it is referred to as wt MHM2-PrP. The 65 amino proximal amino
acids, which are removed during the trimming of PrPSc to PrP27-30
[22], are dispensable for the formation of PrPSc [8,23]. v23-88 desig-
nates the PrP construct in which these codons have been deleted (Fig.
1).
2.3. Cells and transfections
Mouse neuroblastoma (N2a) and CHO cells were grown at 37‡C in
DMEM16 (low glucose) supplemented with 10% fetal calf serum.
N2a-C10 cells [24] stably express the MHM2-PrP chimera. Transient
transfections of the PrP constructs was achieved with the non-liposo-
mal reagent FuGENE 6 (Roche), which was used according to the
manufacturer’s instructions. Cells were harvested 72 h after the trans-
fection.
2.4. Antibodies
Rabbit antiserum R073 binds to both mouse PrP and to MHM2-
PrP [25,26]. MAb 3F4 [21] binds to residues Met108 and Met111 [27] in
chimeric MHM2-PrP but does not recognize the wt mouse PrP
endogenous to N2a cells [20]. Both antibodies were used at a dilution
of 1:5000 (of the serum or the ascitic £uid, respectively). Secondary
antibodies were from Jackson ImmunoResearch (West Grove, PA,
USA).
2.5. DNA constructs
In situ mutagenesis was achieved by the method of Kunkel [28]
using the primer 5P-TCGTGCACGATGCCGTCAATATCACC.
MHM2 was ¢rst ligated into pSL301 (Invitrogen, Carlsbad, CA,
USA) between the SalI and BglII sites, then excised with EcoRI
and HindIII and ligated into pBluescript II SK+ (Stratagene, La Jolla,
CA, USA), where mutagenesis was performed. After con¢rming the
presence of the mutation by sequencing, the mutated gene was excised
from pBluescript with EcoRI and NheI and cloned into the expression
vector pCI-neo (Promega, Madison, WI, USA). Plasmid DNA for
transfections was prepared with the WizardPlus maxiprep DNA pu-
ri¢cation system (Promega).
2.6. Biochemical analysis of PrP
SDS-PAGE, Western immunoblotting and immunoprecipitation of
the PrP isoforms were all carried out as described [24,29]. Cells were
lysed in ice-cold ‘standard’ lysis bu¡er (0.5% Triton X-100, 0.5% Na-
deoxycholate, 150 mM NaCl, 10 mM Tris-Cl, pH 7.5, 10 mM EDTA)
and the lysates were immediately centrifuged for 1 min at 14 000 rpm
in a microfuge. All biochemical analyses were performed on this post-
nuclear fraction. For endoglycosidase H analysis, cell lysates (100 Wl)
were incubated with the enzyme according to the manufacturer’s in-
structions (EndoH, New England Biolabs, MA, USA).
To assess the degree of aggregation of the various PrP isoforms in
cell lysates, we utilized sucrose gradients containing sarcosyl. Assays
in sucrose gradients were performed as follows. Cell lysates were
loaded on top of pre-formed sucrose step gradients prepared with
300 Wl each of 10, 15, 20, 25, 30 and 60% sucrose in TNS (10 mM
Tris, pH 7.5, 100 mM NaCl, 1% sarcosyl). The tubes were spun at
55 000 rpm for 1 h at 4‡C in a TLS-55 rotor (gav = 200 000Ug), 180 Wl
fractions were collected from the top and analyzed as described in
each experiment.
2.7. Biotinylation of cell surface proteins
Proteins at the surface of cells were biotinylated as follows. The
whole procedure was performed at 10‡C. Cells growing in 90 mm
petri dishes were rinsed three times in ice-cold bu¡er A (150 mM
NaCl, 1 mM MgCl2, 0.1 mM CaCl2, 20 mM HEPES, pH 7.4) and
then incubated for 40 min in bu¡er A containing 500 Wg/ml NHS-X-
biotin (water-soluble). The cells were then rinsed three times in ice-
cold bu¡er A supplemented with 50 mM NH4Cl to quench the bio-
tinylation reagent and then lysed in the standard lysis bu¡er. Prior to
immunoprecipitation, lysates were boiled for 30 min in 2% sarcosyl,
diluted 3-fold with TNS, incubated on ice for 60 min and then cen-
trifuged for 1 h at 100 000Ug to remove insoluble material. Antibody
was added to the supernatant for immunoprecipitation, which was
carried out as described [16].
2.8. Immuno£uorescence
To detect PrP on the surface of cells, we labelled live cells as de-
scribed [26] to take advantage of the patching e¡ect caused by the
cross-linking secondary antibody [30]. Cells were cooled to 4‡C and
then sequentially incubated with the mAb 3F4, followed by a secon-
dary anti-mouse IgG coupled to FITC (diluted at 1:2000 and 1:200,
respectively, in 1% BSA in phosphate-bu¡ered saline (PBS)). Follow-
ing extensive washes, the cells were ¢xed with formaldehyde (8% for-
malin in PBS, 4‡C, 15 min) and then quenched by several rinses with
2% NH4Cl in PBS prior to mounting. To detect total PrP, the cells
were ¢xed (8% formalin in PBS, 4‡C, 30 min), rinsed with 2% NH4Cl
in PBS and then permeabilized (0.1% Triton X-100 in PBS, 5 min,
room temperature) prior to their incubation with 3F4 and the sec-
ondary antibody as described above. In both cases, the labelled cells
were mounted in an anti-fading preparation (5% n-propyl gallate,
100 mM Tris-Cl, pH 9, 70% glycerol) [31] and viewed in a Zeiss
Axioplan microscope equipped with epi£uorescence.
3. Results
3.1. PrP-C178A is largely resistant to proteolysis when
expressed in uninfected N2a and CHO cells
Previous studies showed that substituting an alanine for
Cys178 in the truncated v23-88 platform, thereby disrupting
the disul¢de loop, prevents the formation of PrPSc [9]. To
further characterize the properties of PrP with a disrupted
disul¢de loop, we constructed C178A substitution mutants
on two epitopically labelled PrP platforms. First, we used
the truncated v23-88 version of MHM2-PrP which was pre-
viously utilized by Muramoto et al. [9]. Second, since the
amino proximal sequence can modulate the prion properties
of mutant PrP [4,32], we also substituted an alanine for Cys178
in the full length MHM2-PrP gene. These mutants were des-
ignated vC178A and C178A, respectively (Fig. 1).
We ¢rst studied the resistance of the C178A mutants to
proteolysis in transiently transfected N2a (Fig. 2A) and
CHO (Fig. 2B) cells. As controls for these experiments, we
used the wt MHM2-PrP, which behaves as classical PrPC, and
the E199K mutant, which displays ‘prion-like’ properties
Fig. 1. Schematic depiction of the MHM2-PrP gene. Shown are the N-proximal region, the 3F4 epitope, the two cysteines and the two aspara-
gines where N-linked sugars are attached.
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when expressed in CHO cells [6]. Seventy-two h after the
transfection, cells were lysed in standard lysis bu¡er and the
post-nuclear supernatants were digested with proteinase K, at
the indicated concentrations (0^8 Wg/ml, 30 min, 37‡C, see
Fig. 2). Protease-resistant PrP was then analyzed in Western
blots developed with the mAb 3F4, which recognizes MHM2-
based PrP molecules. In N2a cells, both wt PrP and the
E199K construct were entirely digested at 1 Wg/ml (data not
shown) and at 3 Wg/ml proteinase K (Fig. 2A). Interestingly,
however, both constructs were more resistant to proteolysis
when expressed in CHO than in N2a cells (compare Fig.
2A,B). In CHO cells, E199K resisted proteolysis more than
its wt counterpart (Fig. 2B), consistent with previous results
[6].
Surprisingly, sizeable amounts of both C178A and vC178A
were detected in the cells even following incubation with 8 Wg/
ml proteinase K and thus, these mutants were both consider-
ably more protease-resistant than the disease-linked E199K
mutant [6]. As a control for the proteolytic reaction, we
used PrPSc (which resists even higher levels of proteolysis,
20 Wg/ml, 60 min, 37‡C) (Fig. 2C, lane 2), as well as PrPC
(which is entirely degraded by 3 Wg/ml proteinase K) (Fig. 2C,
lane 1).
3.2. The C178A mutants are largely aggregated in 1% sarcosyl
Protease-resistance of PrP as well as of other proteins is
often accompanied by partial insolubility in detergents. To
determine the degree of solubility of the C178A mutants, we
used velocity centrifugation through sucrose gradients (Fig.
3). Post-nuclear supernatants of CHO cells expressing
MHM2-PrP (Fig. 3A), E199K (Fig. 3B), C178A (Fig. 3C)
and vC178A (Fig. 3D,E) were incubated with 1% sarcosyl
for 30 min on ice and then loaded on top of 10^60% sucrose
gradients containing 1% sarcosyl. E199K slightly sedimented
through this gradient, contrasting with the MHM2 control
which stayed primarily in the top 3^4 fractions of the gra-
dient. This is in line with former results [6] and correlates
with the partial protease-resistance of this mutant in CHO
cells (see Fig. 2). Interestingly, both C178A mutants sedi-
mented to a much larger extent than E199K, as more than
half of the material was found in the bottom fractions of the
gradient. The fractions of the vC178A gradient shown in Fig.
3D were further analyzed for their resistance to proteolysis.
One half of each fraction was treated with proteinase K (3 Wg/
ml, 30 min, 37‡C) prior to the Western blot analysis. Results
clearly show (Fig. 3E) that aggregated material indeed resisted
proteolysis. Interestingly, the Mr of the C178A mutants was
often, but not always, more homogeneous in CHO cells than
Fig. 2. C178A and vC178A are largely protease-resistant in N2a and CHO cells. Wt and mutant PrP constructs, as indicated, were transiently
expressed in N2a (A) and CHO (B) cells. Seventy-two h after the transfection, the cells were lysed in standard lysis bu¡er. Post-nuclear super-
natants were digested with proteinase K at the indicated levels (0^8 Wg/ml, 30 min, 37‡C) and then, the resistant PrP species were detected in
Western blots developed with the mAb 3F4. Both C178A mutants were considerably more resistant to proteolysis than the disease-linked mu-
tant E199K. In C, lysates from cells that stably express wt MHM2-PrP were used as controls for these experiments. Lane 1, N2a-C10 cells, di-
gested with 3 Wg/ml proteinase K, 30 min, 37‡C. Lane 2, ScN2a-C10 cells, digested with 20 Wg/ml proteinase K, 1 h, 37‡C.
Fig. 3. The C178A mutants are largely insoluble in sarcosyl. Wt
MHM2 (A), E199K (B), C178A (C) and vC178A (D and E) were
transiently expressed in CHO cells. Post-nuclear supernatants were
brought to 1% sarcosyl and incubated on ice for 30 min and then
analyzed by velocity sedimentation on 10^60% sucrose gradients
containing 1% sarcosyl (55 000 rpm, 1 h, 4‡C). Gradient fractions
were then analyzed for PrP in Western immunoblots developed with
3F4. In C and D, about half of the immunoreactive material was
found in the lower half of the gradient. In E, the fractions were in-
cubated with proteinase K (3 Wg/ml, 30 min, 37‡C) prior to the
Western analysis. The vC178A molecules found in the heavier frac-
tions resisted proteolysis.
Fig. 4. The C178A mutants are sensitive to EndoH. The wt and
mutant PrPs (as indicated) were transiently expressed in N2a cells.
Cell lysates were incubated with EndoH or mock-incubated, as indi-
cated, and then analyzed by Western immunoblotting. C178A and
vC178A were sensitive to EndoH digestion (compare lanes 7 and 8
to lanes 3 and 4).
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in N2a cells, probably re£ecting variations in the glycosylation
pattern in these cells.
3.3. In contrast to wt PrP and E199K, both C178A mutants
remain sensitive to EndoH and do not reach the cell surface
To analyze the subcellular localization of the C178A mu-
tants, we ¢rst used the diagnostic endoglycosidase EndoH
(Fig. 4). Lysates of N2a cells transiently expressing the vari-
ous PrP constructs were incubated either with or without this
endoglycosidase, as indicated in the ¢gure, and then analyzed
in Western immunoblots developed with 3F4. We found that
while MHM2 and v23-88 resisted digestion with EndoH, both
C178A mutants were almost entirely digested under these con-
ditions. Thus, the C178A mutants may not cross the mid-
Golgi stack. This interpretation was con¢rmed by cell surface
biotinylation experiments (Fig. 5). N2a cells were transiently
transfected with the various constructs. Seventy-two h after
transfection, the cell surface was labelled in vivo with a mem-
brane-impermeant sulfo-NHS biotin reagent and the cells
were then lysed. One half of the lysate was subjected to West-
ern analysis developed with 3F4 (lanes 6^10). This con¢rmed
that the PrP constructs were all expressed at comparable lev-
els. The amount of biotinylated PrP was assessed from the
other half of the lysates. Following immunoprecipitation
with 3F4, biotinylated PrP molecules were detected on West-
ern blots developed with streptavidin-HRP (lanes 1^5). We
found that, while the wt constructs and the E199K mutant
were e⁄ciently labelled on the cell surface, little, if any, bio-
tinylated C178A material was detected in these experiments.
We thus conclude that the C178A mutants remain primarily
in the interior of the cells.
3.4. Immuno£uorescent detection of the C178A mutants in
juxtanuclear sites
To further localize the C178A mutants in the cells, we used
immuno£uorescence microscopy (Fig. 6). Like most GPI pro-
teins, wt PrP redistributes to form cell surface patches when
un¢xed cells are incubated with cross-linking antibodies [30].
This property has been used in the past to facilitate the micro-
scopic detection of PrP on the plasma membrane [26,33]. Live
CHO cells transiently expressing MHM2 (Fig. 6A,C) or
C178A (Fig. 6B,D) were immuno-labelled with 3F4, followed
by a secondary antibody conjugated to FITC. As expected,
MHM2 formed cell surface patches under these conditions
(Fig. 6A), whereas no £uorescence could be detected on cells
expressing C178A (Fig. 6B), con¢rming the results of the bio-
tinylation experiment (Fig. 5). Entirely di¡erent results were
Fig. 5. The C178A mutants fail to reach the cell surface. The vari-
ous wt and mutant PrPs (as indicated) were transiently expressed in
N2a cells. Cell surface was labelled with a membrane-impermeant
sulfo-NHS reagent. PrP molecules were immunoprecipitated from
half of the lysates using 3F4. The immunoprecipitates were then an-
alyzed in Western blots developed with streptavidin-HRP, to detect
biotinylated PrP species (lanes 1^5). The other halves of the lysates
were analyzed in Western blots developed with 3F4 (lanes 6^10),
demonstrating that all the mutant PrPs were expressed at similar
levels. In contrast to the control PrP (lanes 1^3), little, if any,
C178A and vC178A (lanes 4 and 5, respectively) was biotinylated in
this experiment, suggesting that they did not reach the cell surface
in large amounts.
Fig. 6. Cytoplasmic accumulation of C178A. CHO cells transiently expressing MHM2 (A and C) and C178A (B and D) were processed for
PrP immuno£uorescent detection using the mAb 3F4. A and B: PrP was detected on the surface of live cells using a cross-linking protocol
that causes the formation of patches (see A). No PrP was detected on the surface of cells expressing the C178A mutants (B). In C and D, cells
were ¢xed and permeabilized prior to the application of the antibody. The speckled PrP immunoreactivity found in the Golgi region of cells ex-
pressing MHM2 (C) contrasted the large juxtanuclear spots found in cells expressing the C178A mutant (D).
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obtained when cells were ¢xed and permeabilized prior to
immuno-labelling (Fig. 6C,D). In most cells expressing
MHM2, a slight reticulated signal could be detected through-
out the cytosol as well as in the Golgi region (Fig. 6C). This
immunoreactivity probably represented PrP transitting in the
secretory pathway en route for the plasma membrane. In cells
expressing C178A, the results were strikingly di¡erent (Fig.
6D). In most of these cells, large, strongly immuno£uorescent
spots were seen. Usually, these spots clustered around the
nucleus, but occasionally, they were scattered in more distal
locations in the cytosol and even in close proximity to the cell
surface. Similar results were also observed in cells expressing
vC178A (not shown). Pre-incubating the mAb 3F4 with a
synthetic peptide including the epitope [27] abolished the im-
muno£uorescent signal, con¢rming the speci¢city of this test
(data not shown).
4. Discussion
Both C178A substitution constructs su¡ered from severe
tra⁄cking abnormalities when expressed in N2a and CHO
cells. They also resisted partial proteolysis and were aggre-
gated in sarcosyl. These metabolic abnormalities may contrib-
ute to their previously observed inability to form PrPSc in
scrapie-infected cells [9], perhaps by barring them from reach-
ing the favorable subcellular locations where PrPSc templates
are found and where additional PrPSc molecules can be man-
ufactured. Tra⁄cking abnormalities have indeed been shown
previously to prevent the formation of PrPSc. When ScN2a
cells were treated with BFA, exit of nascent PrP from the ER-
Golgi was prevented, its association with detergent-insoluble
rafts [34] was suppressed [29] and its transformation into pro-
tease-resistant PrPSc was inhibited [35]. Neither C178A con-
structs reached the cell surface at detectable levels (Figs. 5 and
6) and their sensitivity to deglycosylation by EndoH indicates
that they probably did not traverse the mid-Golgi complex.
The association of the C178A mutants with buoyant, deter-
gent-insoluble rafts [24,34,36] was also largely inhibited (A.Y.,
manuscript in preparation).
The reason for this mislocalization remains to be estab-
lished. We envisage that the C178A mutants could be retained
in the early secretory pathway by at least two mechanisms.
First, the exposed thiol of the remaining cysteine could be
recognized and actively retained, perhaps by forming disul¢de
bonds with ER resident proteins. Studies on immunoglobulins
revealed that the recognition of exposed thiols is one of the
mechanisms that restricts the secretion of unassembled mole-
cules. In the case of Ig-V chains, retention in the ER was
mediated by the COOH-terminal cysteine and correlated
with the formation of disul¢de bonds with protein disul¢de
isomerase and ERp72, among other ER proteins [37]. This
thiol-mediated retention mechanism was shown to function
primarily in the ER. In the case of IgG, it was not operative
in or beyond the Golgi complex [38]. In some cases, thiol
retention mechanisms could be reversed by treating the cells
with a high concentration (ca. 50 mM) of membrane-perme-
ant reducing agents, such as L-mercaptoethanol. Whether
such a treatment will be able to alleviate the tra⁄cking block
of the C178A mutants remains to be seen. Alternatively, it is
also possible that the C178A mutants could be retained in the
ER because they do not attain a native conformation, irre-
spective of thiol retention mechanisms. It is well documented
that disul¢de bonds help the folding process of proteins and
stabilize their native conformation. For instance, native disul-
¢de bonds stabilized both the ¢nal conformation of lysozyme
and that of early folding intermediates [39].
We do not yet know the nature of the large intracellular
structures where the C178A mutants amass. Cells co-stained
with an antibody against the ER chaperone BiP showed the
conventional reticular pattern of the ER, but no distension
(data not shown), suggesting that the C178A mutants did
not accumulate within a BiP-containing subcompartment of
the ER. An intriguing possibility is that, following their fail-
ure to pass the ER folding quality control, the C178A mu-
tants could be dislocated across the ER membrane to the
cytosol for proteasomal degradation (ERAD) and that they
could accumulate within the cytosol following partial failure
of the degradation. Large cytosolic accumulations, located in
centrosomal ‘aggresomes’, were seen following expression of
misfolding mutants of the cystic ¢brosis transmembrane con-
ductance regulator CFTR and of presenilin-1 in cultured cells
[40]. Aggresomal CFTR and PS1 were insoluble in detergents
and had a long half-life (more than 24 h) and could be pro-
duced either by inhibition of proteasome activity or by its
saturation with overexpressed mutants. While a minority of
aggresomal protein was ubiquitinated, most possessed a nor-
mal molecular weight and thus was not conjugated to ubiq-
uitin. Whether PrP with disrupted disul¢de loops accumulates
in aggresomes in cells transiently expressing C178A PrPs re-
mains to be seen. In CHO cells, C178A PrP accumulated in
more than one juxtanuclear spot.
The possibility that mutant PrP could reside within the
cytosol raises intriguing questions. Using ligand blotting,
Oesch and coworkers demonstrated that PrP and especially
its P5 region (corresponding to amino acids 142^174 of Syrian
hamster PrP) binds to the glial intermediate ¢lament molecule
GFAP [41]. As long as PrP was thought to be entirely lumi-
nal, the implications of this a⁄nity could not be appraised. If
PrP was translocated in the cytosol and spared from immedi-
ate proteosomal degradation, however, the way would be
paved for a functional interaction of PrP with intermediate
¢laments of glial cells. It will be interesting to see the e¡ect of
C178A expression in glial cells. Transmembrane PrP proteins
that are not entirely luminal have been described [5,42,43].
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